According to the World Health Organization respiratory diseases constitute a very broad group of disorders of the airways and other structures of the lung including chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases, pulmonary hypertension and pulmonary fibrosis.

We are aware that the development of new inhaled drugs to treat respiratory conditions is a very complex and challenging process that requires specialized testing. Despite enormous medical needs in respiratory medicine only a few classes of effective and safe pharmaceuticals were introduced to the market over the last four decades.

Therefore it is worth emphasizing that our scientists have already performed multiple integrated drug discovery programs for different targets in the area of respiratory diseases. The efforts of Selvita researchers resulted in a solid track record of biophysical, biochemical, and cell-based assays (including HCS-based phentotypic screens) supported by state-of-the-art in vivo models enabling analysis of efficacy and safety of novel drug candidates.

To learn about our expertise and capabilities concerning testing of NCEs against respiratory diseases please visit our sites related to:

Fibrosis
Inflammation
Infection